Problems resulting from the absence of suitably adapted medicinal products for the paediatric population include inadequate dosage information which leads to increased risks of adverse reactions including death, ineffective treatment through under-dosage, non-availability to the paediatric population of therapeutic advances, suitable formulations and routes of administration, as well as use of magistral or officinal formulations to treat the paediatric population which may be of poor quality.
Recital 3, Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…
In forcecited 1×
Judgment of the General Court (Third Chamber) of 14 December 2011. Nycomed Danmark ApS v European Medicines Agency (EMA).Decision
According to recital 3 in the preamble to Regulation No 1901/2006, problems resulting from the absence of suitably adapted medicinal products for the paediatric population include inadequate dosage information, which leads to increased …
14 Dec 2011 · 62009TJ0052